References
- Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med 1998; 338(20): 1438–47
- Stern RA, Robinson B, Thorner AR, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8(2): 181–5
- Solomon B, Glinoer D, Lagasse R, et al. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70(6): 1518–24
- Ross DS. The medical management of Graves' disease. Endoer Pract 1995; 1(3): 193–9
- Törring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine: a prospective, randomized study. J Clin Endocrinol Metab 1996; 81(8):2986–93
- Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab 1995; 80(5):1481–4
- Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324(14):947–53
- DeGroot LJ, Mangklabruks A, McCormick M. Comparison of RA 1311 treatment protocols for Graves' disease. J Endocrinol Invest 1990; 13(2): 111–8
- Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course ot Graves' ophthalmopathy. N Engl J Med 1998; 338(2): 73–8
- Haddad G. Is it hyperthyroidism? You can't always tell from the clinical picture. Postgrad Med 1998; 104(1): 42–4, 53–5, 59